WO2013021057A2 - Method of neonatal serological diagnosis - Google Patents
Method of neonatal serological diagnosis Download PDFInfo
- Publication number
- WO2013021057A2 WO2013021057A2 PCT/EP2012/065737 EP2012065737W WO2013021057A2 WO 2013021057 A2 WO2013021057 A2 WO 2013021057A2 EP 2012065737 W EP2012065737 W EP 2012065737W WO 2013021057 A2 WO2013021057 A2 WO 2013021057A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- igg3s
- ighg3
- alleles
- newborn
- peptides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
- G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
- G01N2333/445—Plasmodium
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa
- G01N2333/45—Toxoplasma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a method for detecting amino acid polymorphisms of immunoglobulin heavy chains.
- the method allows in particular the determination of the allotypes of immunoglobulins in a blood sample, in particular making possible to identify and quantify immunoglobulins from the mother and from the newborn.
- the invention also relates to the use of this method as a serological diagnostic tool in the area of vertically transmitted diseases.
- Chagas disease also known as South American trypanosomiasis, a parasitic infection caused by Trypanosoma cruzi, which is rife in the tropical regions of South America and Central America.
- congenital Chagas disease can be diagnosed by microscopic examination of the parasite in a blood sample and/or by amplification of portions of parasitic genes by PCR (Schijman et al., J. Antimicrob. Chemother., 2003, 52: 441-449).
- these techniques are limited by obstacles that prevent from reaching a definitive diagnostic conclusion.
- toxoplasmosis a parasitic infection caused by the protozoan Toxoplasma gondii. Although infection by this parasite occurs in all regions of the world, it is more prevalent in certain parts of Europe, the Caribbean and South America than in Asia, the United States or Australia. Congenital infection can be diagnosed by PCR, and a Western blot qualitative test is used for comparing the immunological profiles of the IgM and IgG from the mother and the child, without determining the amounts of immunoglobulins (Pinon et al., J. Clin. Microbiol, 2001, 39: 2267-2271). However, this test requires maternal plasma to be collected shortly after birth, and its use is therefore exclusively perinatal.
- EI A enzyme immunoassay
- Malaria is another example of parasitic disease for which understanding of the mechanisms of acquisition of specific natural immunity by the infant might be of help for proposing public health measures for protecting groups at risk and for better targeting future strategies of antimalarial vaccination.
- Malaria is due to a parasite of the genus Plasmodium, of which the species Plasmodium falciparum is the most common and the most pathogenic in humans and that which is responsible for fatal cases. Malaria affects about a hundred countries in the world, particularly in the underprivileged tropical zones of Africa, Asia and Latin America. It mainly affects children under 5 years of age and pregnant women, who are particularly vulnerable because the placenta constitutes a target where the parasites may accumulate. In a pregnant woman, malarial infection can cause a whole range of detrimental effects: spontaneous abortion, premature birth, low birth weight, congenital transmission, and neonatal death.
- the present invention relates generally to a method for distinguishing between the immunoglobulins of the mother and of the neonate in a blood sample taken during the first months of the child's life.
- This method is, in particular, applicable to the diagnosis of vertically transmitted diseases. More specifically, the inventors have shown that it is possible to use the allotype polymorphisms of immunoglobulins or other polymorphic amino acids of the heavy chains of immunoglobulins for separately identifying and quantifying the immunoglobulins of the mother and of the newborn. They have developed a technique for differentially detecting and quantifying, in the neonate's plasma, the immunoglobulins G (IgG) of the mother and those of the child.
- IgG immunoglobulins G
- This technique is based on a proteomic approach and makes use of the individual characteristics of IgG3s, the most polymorphic IgG subclass.
- the inventors have identified, among the peptides obtained by a series of enzymatic digestions performed on the Fc fragment of purified IgG3s, a list of peptides indicative of the identity of G3m and IGHG3 alleles.
- the method developed was validated on blood samples from a Beninese mother and her baby and the results were confirmed by previous determination of the polymorphism of the IgG allotypes using an immunohaematologic technique allowing definition of the G3m alleles of the child from determinations performed on the child and on his biological parents (see Examples).
- the present invention provides an in vitro method for detecting antibodies in a newborn, the method comprising steps of: determining, by mass spectrometry, the G3m and IGHG3 alleles present in a blood sample obtained from the newborn, the blood sample comprising IgG3s of the newborn and maternal IgG3s transmitted to the newborn during pregnancy; comparing the G3m and IGHG3 alleles of the IgG3s present in the blood sample obtained from the newborn to the G3m and IGHG3 alleles of the IgG3s present in a blood sample obtained from the newborn's mother; and detecting, and optionally quantifying, the IgG3s of the newborn.
- the blood sample obtained from the newborn is obtained between the birth and the 9 th month of the newborn's life.
- the blood sample obtained from the newborn is a plasma sample.
- a method according to the invention further comprises steps of: isolating the IgG3s present in the blood sample obtained from the newborn; submitting the isolated IgG3s to an enzymatic digestion in order to obtain a mixture of proteotypic peptides of IgG3; and detecting, by mass spectrometry, the presence of at least one peptide distinctive of G3m and/or IGHG3 alleles in order to determine the alleles of the IgG3s present in the blood sample obtained from the newborn.
- the step of isolating the IgG3s present in the blood sample from the newborn may be performed using any appropriate method.
- the IgG3s are isolated by affinity chromatography (for example using a Protein A column and/or a Protein G column).
- the IgG3s are isolated by liquid chromatography, in particular by Fast Protein Liquid Chromatography (FPLC).
- FPLC Fast Protein Liquid Chromatography
- the step of submitting the isolated IgG3s to a proteolysis or an enzymatic digestion may be performed using any appropriate method leading to a mixture of proteotypic peptides of IgG3.
- the enzymatic digestion comprises a digestion in the presence of the endoproteinase AspN followed by a digestion in the presence of trypsin, or alternatively a digestion in the presence of both AspN and trypsin.
- the at least one peptide distinctive of G3m and/or IGHG3 alleles allowing determination of the alleles of the IgG3s present in the blood sample obtained from the newborn, is selected from the group consisting of the peptides of SEQ ID NOs: 1 to 32 and any combination thereof.
- the mass spectrometry analysis performed in a method according to the invention is carried out using a tandem mass spectrometry technique, such as MALDI-TOF/TOF, ESI-LTQ-Orbitrap or SRM MS/MS.
- a tandem mass spectrometry technique such as MALDI-TOF/TOF, ESI-LTQ-Orbitrap or SRM MS/MS.
- the alleles of the IgG3s present in the blood sample of the newborn's mother may be determined using any appropriate method.
- the allotypes of the IgG3s present in the blood sample of the mother are determined using an immunohaematologic technique, preferably a technique of haemagglutination inhibition.
- the alleles of the IgG3s present in the blood sample of the mother are determined using a method according to the invention.
- the present invention provides an in vitro method for diagnosing, in a newborn, an infectious disease caused by a pathogen, the method comprising steps of: determining, by mass spectrometry, the alleles of the pathogen- specific IgG3s present in a blood sample obtained from the newborn, the blood sample comprising pathogen-specific IgG3s of the newborn and pathogen-specific IgG3s of maternal origin transmitted to the newborn during pregnancy; comparing the alleles of the pathogen- specific IgG3s present in the blood sample of the newborn to the alleles of the IgG3s present in a blood sample obtained from the newborn's mother; and detecting, and optionally quantifying, the pathogen- specific IgG3s of the newborn.
- the blood sample obtained from the newborn is obtained between the birth and the 9 th month of the newborn's life.
- the blood sample obtained from the newborn is a plasma sample.
- a diagnostic method further comprises: isolating the pathogen-specific IgG3s present in the blood sample obtained from the newborn; submitting the isolated pathogen- specific IgG3s to an enzymatic digestion in order to obtain a mixture of proteotypic peptides of IgG3; and detecting, by mass spectrometry, among the mixture of proteotypic peptides of IgG3, the presence of at least one peptide distinctive of G3m and/or IGHG3 alleles in order to determine the alleles of the pathogen-specific IgG3s present in the blood sample obtained from the newborn.
- the at least one peptide distinctive of G3m and/or IGHG3 alleles, allowing determination of the alleles of the pathogen-specific IgG3s present in the blood sample obtained from the newborn is selected from the group consisting of the peptides of SEQ ID NOs: 1 to 32 and any combination thereof.
- the enzymatic digestion of the pathogen-specific IgG3s is carried out in the presence of AspN and trypsin.
- the infectious disease diagnosed by a method according to the invention is a viral infectious disease, and the isolated IgG3s are specific of the virus responsible for the infectious disease. In other embodiments, the infectious disease diagnosed by a method according to the invention is a bacterial infectious disease, and the isolated IgG3s are specific of the bacteria responsible for the infectious disease.
- the infectious disease diagnosed by a method according to the invention is a parasitic infectious diease
- the isolated IgG3s are specific of the parasite responsible for the infectious disease.
- the isolated IgG3s are specific of the parasite Plasmodium falciparum
- the isolated IgG3s are specific of the parasite Trypanosoma cruzi
- the isolated IgG3s are specific of the parasite Toxoplasma gondii.
- the step of isolating the pathogen- specific IgG3s present in the blood sample from the newborn may be performed using any suitable method.
- total IgG3s are first isolated from the blood sample, for example by affinity chromatography ou by FPLC; and then the pathogen-specific IgG3s are isolated from the total IgG3s.
- Isolating the pathogen-specific IgG3s from the total IgG3s may be performed using any appropriate technique, for example via formation of an immunocomplex resulting from contact between the total IgG3s with a pathogen- specific antigenic preparation.
- the other steps in a diagnostic method according to the invention may be carried out like when total IgG3s are used instead of pathogen-specific IgG3s.
- the alleles of the IgG3s present in the blood sample obtained from the newborn's mother may be determined using any appropriate method on the total IgG3s or on the pathogen-specific IgG3s.
- the determination is carried out using an immunohaematologic technique, preferably a technique of haemagglutination inhibition.
- the determination is carried out using a method according to the invention. Indeed, as will be recognized by one skilled in the art, a method according to the invention may be used to determine the polymorphism of the IgG alleles of an individual at any stage of his or her life, i.e., aside from any consideration of the problems connected with the diagnosis of vertically transmitted diseases in newborns.
- the present invention provides a method for determining the alleles of IgG3s of an individual, the method comprising a step of: determining, by mass spectrometry, the amino acid polymorphism of the heavy gamma chains of IgG3s present in a blood sample obtained from the individual.
- this method further comprises steps of: isolating the IgG3s present in the blood sample from the individual; submitting the isolated IgG3s to an enzymatic digestion in order to obtain a mixture of proteotypic peptides of IgG3; and detecting, by mass spectrometry, among the mixture of proteotypic peptides of IgG3, the presence of at least one peptide distinctive of G3m and/or IGHG3 alleles in order to determine the amino acid polymorphism of the heavy gamma chains of IgG3s present in the blood sample from the individual.
- the enzymatic digestion comprises a digestion in the presence of the endoproteinase AspN followed by a digestion in the presence of trypsin, or a digestion in the presence of both AspN and trypsin; and the least one peptide distinctive of G3m and/or IGHG3 alleles is selected from the group consisting of the peptides of SEQ ID NOs: 1 to 32 and any combination thereof.
- the present invention relates to the use of a plurality of peptides distinctive of G3m and/or IGHG3 alleles to calibrate a mass spectrometer used in a method according to the invention.
- the plurality of peptides distinctive of G3m and/or IGHG3 alleles is selected from the group consisting of the peptides of SEQ ID NOs: 1 to 32 and any combination thereof.
- the present invention provides a kit for the determination of the alleles of the IgG3s of an individual using a method according to the invention, and a kit for the diagnosis of a vertically transmitted infectious disease in a newborn according to the invention, each kit comprising a plurality of peptides disctintive of G3m and/or IGHG3 alleles belonging to the group consisting of the peptides of SEQ ID NOs: 1 to 32 and any combination thereof, wherein the peptides are intended to be used for calibrating the mass spectrometer used in the method.
- Figure 1 shows the migration, on acrylamide gel, of the purification fractions obtained from passage of a plasma sample on the column of Protein A and then of Protein G.
- A 12% SDS-PAGE in non-reducing conditions.
- AF1 to AF3 Successive filtrate fractions of a Protein A column containing plasma proteins including IgG3s
- AE Elution fraction of a Protein A column containing IgGl, IgG2, IgG4
- GEl to GE2 Consecutive elution fractions of a Protein G column containing IgG3s.
- B 12% SDS- PAGE in reducing conditions.
- GEl and GE2 Consecutive elution fractions of a Protein G column containing IgG3.
- Figure 2 is a list of the 32 discriminating peptides of G3m and/or IGHG3 alleles observable after theoretical cleavage by an AspN/trypsin combination of the heavy chain of the IgG3s and whose mass was determined for measurement using MALDI and ESI-ORBITRAP.
- the amino acids shown in bold are involved in the discrimination between the IGHG3 alleles included in the composition of the G3m alleles.
- the peptides are represented by showing the enzymatic cleavage sites by a point (" . ") and the amino acids before and after the enzymatic cleavages. A single cleavage fault is tolerated.
- the carbamidomethylated cysteines are shown as "C c ".
- the m/z masses (Mox) are the masses calculated taking into account the possibility of oxidation of the methionine (M).
- the m/z masses determined with ESI-ORBITRAP are the masses of the bi- / tri- / and tetra-charged peptides.
- Figure 3 is a MALDI-TOF spectrum of a heavy-chain tryptic digestion of purified IgG3s from a plasma sample from an individual of European origin.
- the tryptic peptides assigned corresponding to the masses labelled (*) are shown in red (green* for the propionamidated cysteines).
- the precursor selected with m/z of 2314.06 was submitted to CID fragmentation in MALDI in MS/MS mode.
- the fragmentation spectrum gives a Mascot result that unambiguously confirms the presence of the IGHG3 347-365 peptide: R.WQQGNIFSCSMHEALHNR.F whose mass makes it possible to discriminate the variations of amino acids.
- Figure 4 is a graph showing the relative abundance of discriminating peptides of two G3m alleles as a function of different volume ratios of the two iso forms.
- Figure 5 is a graph showing the relative abundance of the peptide WQQGNIFSCSVMHEALHNR in field samples.
- CI blood from the mother
- CO umbilical cord blood
- M blood from the child at 3, 6 and 9 months; three technical repetitions of the experiment.
- A The peptide signals were measured by LTQ ORBITRAP and the relative abundance was calculated by the Progenesis LC-MS software.
- B The peptide signals were measured by SRM.
- the present invention generally relates to a method for determining the polymorphism of IgG allotypes and other amino acid polymorphisms of the IgG heavy gamma chains in an individual.
- this method allows to distinguish and/or to quantify the immunoglobulins of a mother and of her newborn in a blood sample taken during the first months of the child's life.
- This method finds application in the area of diagnosis of vertically transmitted diseases in neonates.
- the transport of maternal antibodies during pregnancy is limited to the immunoglobulins G (IgGl, IgG2, IgG3 and IgG4). These immunoglobulins persist in the neonate for the first 6 months of life.
- the methods of the invention are based on the use of the allotype polymorphisms or other amino acid polymorphisms of the heavy chains of immunoglobulins G for separately identifying and quantifying the immunoglobulins of the mother and those of the newborn in a blood sample obtained from the child.
- the terms "neonate”, “newborn” and “infant” are used interchangeably. These terms denote a human being during the first months of its life.
- first months of life refers to a period from birth to the 9 th month (inclusive) after birth.
- Gm allotype are used interchangeably.
- the Gm allotypes (Lefranc and Lefranc, "The Human IgG Subclasses: Molecular analysis of structure, function and regulation", Pergamon Press, Oxford, 1990, pp. 43-78) are antigenic determinants localized on the heavy chains of three of the four IgG subclasses (IgGl, IgG2, IgG3 and IgG4) which allow distinction between individuals of the same species. They correspond, at the molecular level, to the substitution of one or more amino acids in the polypeptide sequence of the immunoglobulins.
- the polymorphic Gm allotypes are encoded by alleles of genes that are closely related and inherited by particular combinations called haplotypes.
- the 11 Gm haplotypes that are known and their frequencies vary strongly from one population to another, thus defining four major groups: "African”, “Asian”, “European” and “European and Asian” (see Table 1).
- Table 1 List of Gm ha lotypes found in human populations.
- Gm allotypes of gamma 1, gamma2 and gamma3 chains are presented in the order of the position in genes in sub-classes on the IGHG gene (G3, Gl and G2), with “ ; “ to separate the sub-classes and " , “ to separate the allotypes. " .. " designates the absence of G2m allotype.
- the Gm system is composed of 18 allotypes (see Table 2).
- a method according to the invention is based on the identification, by mass spectrometry, of the allotypes of the IgG3s present in a blood sample from the neonate (or of other polymorphic amino acids of the gamma chains of the IgG3s), and therefore comprises the determination, by mass spectrometry, of the G3m and IGHG3 alleles present in the blood sample obtained from the newborn.
- a method of detection comprising the determination, by mass spectrometry, of the allotypes of the IgGls or of the IgG2s, or other polymorphic amino acids of the gamma chains of the IgGls or of the IgG3s, present in a blood sample from the neonate.
- a method of detection comprising the determination, by mass spectrometry, of the allotypes of the IgG3s and of the IgGls (or other polymorphic amino acids of the gamma chains of the IgG3s and of the IgGls), or of the allotypes of the IgG3s and of the IgG2s (or other polymorphic amino acids of the gamma chains of the IgG3s and of the IgG2s), or of the allotypes of the IgGls, IgG2s and IgG3s (or other polymorphic amino acids of the gamma chains of the IgGls, IgG2s and IgG3s), present in a blood sample from the neonate.
- Table 2 Localization of Gm allotypes on the three sub-classes of immunoglobulins G.
- a method according to the invention comprises the detection of one or more peptides distinctive of G3m and/or IGHG3 alleles.
- peptide distinctive of G3m and/or IGHG3 alleles refers to a proteotypic peptide that is indicative (or that is a signature) of the identity of a G3m allele and/or an IGHG3 allele.
- proteotypic peptide is a peptide that is generated by enzymatic digestion of a given protein in a reproducible and specific manner with respect to the protein and which can be detected by mass spectrometry.
- TKPREEQYNSTFR (SEQ ID NO: 2)
- WQQGNIFSC C SVMHEALHNRYTQK (SEQ ID NO: 32), wherein C c represents a carbamidomethylated cysteine.
- the present invention therefore relates to a plurality of peptides distinctive of G3m and/or IGHG3 alleles selected from the group consisting of the peptides listed below or any combination of these peptides.
- the present invention also relates to the use of these peptides in a method according to the invention.
- a list of peptides distinctive of Glm and/or IGHGl alleles i.e., distinctive of the IgGl heavy chain
- G2m and/or IGHG2 alleles i.e., distinctive of the IgG2 heavy chain
- the methods according to the invention are carried out using a blood sample from the neonate.
- a plasma sample is obtained from the blood sample.
- Methods for obtaining plasma from human blood are known in the art.
- a blood (or plasma) sample from a newborn comprises IgGs from the newborn and IgGs of maternal origin transmitted in utero.
- the "IgGs from the newborn” include fetal IgGs (i.e., IgGs synthesized by the fetus during pregnancy) and IgGs synthesized by the newborn after birth.
- the methods according to the invention are carried out on a single subclass of immunoglobulins among IgGl, IgG2 and IgG3.
- the methods are carried out on the IgG3s present in the blood or plasma sample from the newborn.
- the analysis by mass spectrometry is carried out on the blood or plasma sample.
- the IgG3s present in the blood or plasma sample are isolated and then submitted to enzymatic digestion.
- the step of isolating the IgG3s can be performed by any suitable method; the isolation method used is not a critical or limiting element.
- the IgG3s may be isolated by affinity chromatography. As described in the Examples presented below, it is for example possible to isolate the IgG3s from a plasma sample by carrying out affinity chromatography on a column of Protein A and/or affinity chromatography on a column of Protein G. Protein A and Protein G columns are available commercially, and one skilled in the art is able to select the appropriate elution conditions for obtaining purified or substantially purified IgG3s.
- the IgG3s may be isolated by liquid chromatography, for example by fast protein liquid chromatography.
- the system for fast protein liquid chromatography or FPLC (Sheehan et al., Meth. Mol. Biol, 2004, 244: 253-258) was developed by Pharmacia (now GE Healthcare) in 1982 for separating or purifying proteins or other macromolecules from complex mixtures.
- the FPLC apparatus (A TA FPL CTM and BioLogic DuoflowTM) is currently marketed by GE Healthcare and Bio-Rad Laboratories.
- the columns used in FPLC can separate macromolecules according to their size, their charge distribution, their hydrophobicity, or by affinity.
- a method of separation using the FPLC technique may allow standardization of the purification of IgG3s and optimization of the amount of purified IgG3s recovered.
- proteolytic peptides of IgG3 comprising proteotypic peptides of IgG3 ⁇ i.e., peptides generated by enzymatic digestion in a reproducible and specific manner with respect to the immunoglobulins G3).
- proteolysis and “enzymatic digestion” are used here interchangeably. They refer to the fragmenting or cutting of a protein into several pieces (peptides) under the action of an enzyme or of a combination of enzymes.
- the method of enzymatic digestion used will have to be modelled on the conditions of theoretical enzymatic cleavage used for identifying the peptides distinctive of G3m and/or IGHG3 alleles.
- the proteolysis of the IgG3s isolated from the neonate blood sample is therefore be carried out by digestion in the presence of endoproteinase AspN followed by digestion in the presence of trypsin, or by digestion in the presence of endoproteinase AspN and of trypsin.
- the IgG3s are submitted to reduction, for example in the presence of dithiothreitol (DTT), which reduces the disulphide bonds of the immunoglobulins to thiols and thus separates the heavy chains from the light chains, and then to protection of the thiol groups of the heavy chain of IgG3, for example by alkylation in the presence of chloroacetamide.
- DTT dithiothreitol
- Mass spectrometry is a physical technique of analysis for detecting and identifying molecules of interest by measuring their mass, characterizing their chemical structure, and optionally quantifying them.
- the principle of mass spectrometry is based on the gas phase separation of charged molecules (ions) as a function of their mass/charge ratio (m/z).
- analysis by mass spectrometry can be performed using any suitable technique of mass spectrometry allowing for peptides to be detected in a complex mixture and for their sequences to be inferred.
- the sample comprising the mixture of proteolytic peptides of IgG3 can be introduced directly into the mass spectrometer in liquid or solid form (e.g. , deposition on a MALDI plate) or by coupling the mass spectrometer to a separative method (e.g., liquid chromatography, capillary electrophoresis).
- a separative method e.g., liquid chromatography, capillary electrophoresis
- the peptides of the mixture are vaporized and ionized (the ionization source can be used either in positive mode for studying positive ions, or in negative mode for studying negative ions).
- the ionization source can be used either in positive mode for studying positive ions, or in negative mode for studying negative ions.
- ESI electrospray ionization
- MALDI matrix-assisted laser desorption ionization
- the ions are then separated by an analyzer as a function of their mass/charge ratio (m/z).
- the analyzer is a high-resolution analyzer that provides accurate measurement of the monoisotopic mass of an ion and then infers its composition after fragmentation.
- a high-resolution analyzer can be time-of- flight (TOF), Fourier transform ion cyclotron resonance (FTICR), the linear trap quadrupole Orbitrap (LTQ-Orbitrap) or a quadrupole filter (QqQ). These analyzers can be coupled together for conducting tandem mass spectrometry experiments (MS/MS). In tandem mass spectrometry, a first analyzer separates the ions, a collision cell fragments the ions, and a second analyzer separates the fragmented ions. Certain analyzers, such as the LTQ-Orbitrap, provide for ion fragmentation and direct analysis of the fragments.
- TOF time-of- flight
- FTICR Fourier transform ion cyclotron resonance
- LTQ-Orbitrap linear trap quadrupole Orbitrap
- QqQ quadrupole filter
- the mixture of proteolytic peptides of IgG3 is analyzed by a tandem mass spectrometry technique, for example MALDI in MS/MS mode, notably MALDI-TOF/TOF or electrospray in MS/MS mode (ESI-LTQ-Orbitrap).
- the mass spectrometer is coupled to a nano-liquid chromatography (nLC) system. The mass measurements of the peptides and of their respective fragments allow determination of the sequence of these fragments (manually or by means of specialized software).
- the mixture of proteolytic peptides of IgG3 is analyzed by SRM (selected reaction monitoring) MS/MS.
- SRM is a method used in tandem mass spectrometry in which an ion of a particular mass is selected in the first stage of a tandem mass spectrometer and an ion product of a fragmentation reaction of the precursor ion is selected in the second mass spectrometer stage for detection.
- the purpose of mass spectrometry analysis is to detect, in the mixture of proteolytic peptides of IgG3, one or more peptides distinctive of G3m and/or IGHG3 alleles, and thus determine the alleles of the IgG3s (i.e. , the G3m and IGHG3 alleles) present in the neonate blood sample (see Table 4).
- the sample from the newborn contains both IgG3s of the newborn and maternal IgG3s transmitted during pregnancy, it is necessary to compare the G3m and IGHG3 alleles determined for the IgG3s present in the newborn blood sample with the G3m and IGHG3 alleles of the IgG3s from the mother in order to deduce the G3m and IGHG3 alleles of the IgG3s of the newborn.
- the G3m and IGHG3 alleles of the IgG3s present in a blood sample obtained from the mother can be determined by any suitable method.
- this determination is carried out by means of an immunohaematologic technique, notably a technique of haemagglutination inhibition (Lefranc et ah, Acta Anthropogenetica, 1976, 1 : 34-45; Dugoujon et ah, Vox Sanguinis, 1989, 57: 133-136; Field and Dugoujon, Gen. Epidemiol, 1989, 6: 31-33).
- an immunohaematologic technique notably a technique of haemagglutination inhibition (Lefranc et ah, Acta Anthropogenetica, 1976, 1 : 34-45; Dugoujon et ah, Vox Sanguinis, 1989, 57: 133-136; Field and Dugoujon, Gen. Epidemiol, 1989, 6: 31-33).
- the G3m and IGHG3 alleles of the IgG3s present in the mother's blood sample are determined by a method of the invention (see below).
- the methods of the invention for distinguishing the IgGs of the mother and those of the newborn in a blood sample taken during the first months of the child's life find application in the area of diagnosis of vertically transmitted diseases.
- vertically transmitted disease refers to any disease transmitted from the mother to the child during pregnancy, in particular infectious diseases.
- infectious diseases that can be diagnosed using a method according to the invention include bacterial infectious diseases, viral infectious diseases, and parasitic infectious diseases.
- the diagnostic methods according to the invention are particularly interesting when the available methods for detecting the antigen of viral, parasitic or bacterial origin are not reliable.
- a method according to the invention is used for diagnosing a parasitic infectious disease in a neonate, in particular a parasitic disease caused by a protozoan.
- parasitic diseases that can be diagnosed by a method of the invention include, but are not limited to, malaria; toxoplasmosis; Chagas disease; sleeping sickness - also called African trypanosomiasis - which is caused by a flagellate protozoan, Trypanosoma brucei ssp. gambiense or Trypanosoma brucei ssp.
- African trypanosomiasis which is caused by a flagellate protozoan, Trypanosoma brucei ssp. gambiense or Trypanosoma brucei ssp.
- Rhodesiense babesioses, which are rare diseases related to malaria and caused by a protozoan of the genus Babesia (B.
- a method of the invention is used for diagnosing malaria, toxoplasmosis, Chagas disease or sleeping sickness.
- a method according to the invention is used for diagnosing a bacterial infectious disease in a neonate.
- congenital fetopathies of a bacterial nature that can be diagnosed by a method of the invention include, but are not limited to, infections by streptococcus B (streptococcosis), Listeria monocytogenes (listeriosis), Treponema pallidum (syphilis), Chlamydia trachomatis (chlamydiosis) or mycoplasma infections.
- a method according to the invention is used for diagnosing a viral infectious disease in a neonate.
- congenital fetopathies of a viral nature that can be diagnosed by a method of the invention include, but are not limited to, rubella, chickenpox, and infections with Parvovirus B19 (erythema infectiosum), cytomegalovirus (cytomegalic inclusion disease), or with herpes simplex virus.
- a method of the invention When a method of the invention is used for diagnosing an infectious disease, it is carried out as described above, but on the pathogen- specific IgG3s (parasite, virus or bacterium) responsible for the disease to be diagnosed rather than on the total IgG3s.
- the terms "paratite-specific IgG3s”, “virus-specific IgG3s” and “bacterium-specific IgG3s” denote the immunoglobulins G3 that are produced by the immune system of the human body in response to the parasitic, viral and bacterial pathogen, respectively.
- the diagnostic techniques according to the invention therefore require a step of isolation of the pathogen-specific IgG3s present in the neonate blood sample to be tested.
- the pathogen-specific IgG3s may be isolated by any suitable method known in the art.
- said isolation may be performed via formation of an immune complex ⁇ i.e., an antigen-antibody complex) resulting from contact between purified IgG3s with a specific antigenic preparation.
- an immune complex ⁇ i.e., an antigen-antibody complex
- the immune complexes can be dissociated to recover the IgG3s specific to the pathogen, for example by application of an acidic buffer solution.
- the antigenic preparation used for isolating the pathogen-specific IgG3s can be a parasitic extract of Trypanosoma cruzi obtained by lysis of an exponential culture of epimastigotes in fetal calf serum (Flechas et ah, BMC Infectious Diseases, 2009, 9: 186).
- the antigenic preparation used for isolating the pathogen- specific IgG3s can be a soluble parasitic extract of Toxoplasma gondii obtained from an in vitro culture of tachyzoites in murine cells (Fatoohi et al, Clin.
- the antigenic preparation used for isolating the pathogen-specific IgG3s can be a recombinant Protein AMAl (Apical Membrane Protein 1) of the asexual blood stages of Plasmodium falciparum (Nebie et al, Infection and Immunity, 2008, 76: 759-766).
- the antigenic preparation may be a parasitic extract of P. falciparum obtained from an in vitro culture of a parasitic line enriched to more than 50% of schizonts (Fievet et al, Am. J. Trap. Med. Hyg., 1995, 53: 612-617).
- a method of diagnosis according to the invention is therefore carried out as described above except that it is performed on the IgG3s specific of the pathogen responsible for the disease to be diagnosed and not on the total IgG3s.
- MRM Multiple Reaction Monitoring
- SRM Select Reaction Monitoring
- the "pathogen-specific IgG3s of the newborn" isolated from the blood sample comprise pathogen-specific IgG3s of maternal origin and transmitted during pregnancy and, if congenital transmission has occurred, pathogen- specific IgG3s synthesized by the fetus. They can optionally contain pathogen-specific IgG3s synthesized by the newbron in response to exposure to the pathogen after birth.
- the G3m and IGHG3 alleles of the pathogen-specific IgG3s isolated from a newsborn blood sample determined by mass spectrometry are compared to the G3m and IGHG3 alleles of the IgG3s of the mother.
- the allotypes of the IgG3s of the mother can be determined by a classical method of immunohaematology or by a method according to the present invention.
- the determination of the G3m allotypes of the mother can be performed on the total IgG3s or on the pathogen-specific IgG3s, and both determinations should lead to the same result since the polymorphisms are located on the constant domains of the gamma3 heavy chains.
- the definitive diagnosis of the congenital disease may be based solely on a method of diagnosis according to the invention.
- a clinical diagnosis may be established based on the results of a method according to the invention combined with the results of other methods of diagnosis (for example, microscopic observation of the parasite in a newborn blood sample or amplification of portions of genes of the pathogen by PCR).
- the physician can make an informed decision to initiate drug treatment for the newborn, to interrupt drug treatment administered preemptively, or to continue said treatment.
- a method according to the invention may be used for determining the Gm and IGHG alleles of the IgGs of an individual at any stage of life, i.e., aside from any consideration of the problems connected with the diagnosis of vertically transmitted diseases in newborns.
- This is all the more important that the classical method for determining Gm allotypes, which is a serological method of haemagglutination inhibition using erythrocytes of blood group O Rh+ coupled to anti-Rh antibodies of known Gm allotypes and to monospecific anti- allotype antibodies, will soon no longer be available. Indeed, the collections of monospecific anti-allotype and anti-RhD sera, which in the past were obtained from pregnant women and from blood donations, are practically exhausted.
- the present invention therefore also relates to a method for determining the Gm and IGHG alleles of IgGs of an individual, the method comprising a step of: determining, by mass spectrometry, the G3m and IGHG3 alleles of the IgG3s present in a blood sample from the individual.
- the method comprises: isolation of the IgG3s present in the blood sample; proteolysis of the IgG3s isolated to obtain a mixture of proteolytic peptides of IgG3; and detecting, by mass spectrometry, in the mixture of proteolytic peptides of IgG3, the presence of at least one peptide distinctive of G3m and/or IGHG3 alleles in order to determine the G3m and IGHG3 alleles of the IgG3s of the individual.
- the peptides distinctive of G3m and/or IGHG3 alleles belong to the group consisting of the peptides of sequence SEQ ID NO: 1 to 32; and the proteolysis of the IgG3s is carried out in the presence of endoproteinase AspN and trypsin.
- the term "individual”, as used in the context of the present invention, refers to a human being who has passed the infant stage, i.e., a human being more than 6 or 9 months of age (when the immunoglobulins transmitted from the mother have been eliminated completely).
- the steps of isolation and of proteolysis of the IgG3s may be carried out as described above.
- the description of the present invention focuses on the determination of the allotypes, or other amino acid polymorphisms, of IgG3s, but, as pointed out above, it is also conceivable to develop a method according to the invention comprising the determination, by mass spectrometry, of the allotypes, or other amino acid polymorphisms, of IgGls' or of IgG2s' gamma chains of an individual.
- a method according to the invention comprising the determination, by mass spectrometry, of the allotypes, or other amino acid polymorphisms, of IgG3s and IgGls of an individual, or of the allotypes, or other amino acid polymorphisms, of IgG3s and IgG2s of an individual, or of the allotypes, or other amino acid polymorphisms, of IgGls, IgG2s and IgG3s of an individual.
- kits comprising materials useful for carrying out a method according to the invention.
- the present invention provides a kit for determining the polymorphism of the heavy gamma chain of IgG3s of an individual and a kit for diagnosing a vertically transmitted disease in a neonate, in particular a congenital parasitic disease.
- a kit according to the invention comprises a plurality of peptides distinctive of G3m and/or IGHG3 alleles belonging to the group consisting of the peptides of sequence SEQ ID NO: 1 to 32 and any combination of these peptides. These peptides will be used advantageously for calibrating the mass spectrometry apparatus used.
- the kit can further comprise instructions for carrying out the mass spectrometer calibration.
- “Calibration”, as used herein, refers to any procedure for adjusting or calibrating the mass spectrometer utilized in a method according to the invention.
- the kit comprises all the peptides distinctive of G3m and IGHG3 alleles (SEQ ID NO: 1-32) and can therefore be used and marketed throughout the world.
- the kit only comprises the peptides distinctive of G3m and/or IGHG3 alleles necessary for determining a haplotype of the "African” type or of the "Asian” type or of the "European” type for the geographically localized use and marketing of the kit.
- the peptides distinctive of G3m and/or IGHG3 alleles useful for determining a haplotype of the "African" type are the peptides of sequence SEQ ID NO: 2, SEQ ID NO: 5-6, SEQ ID NO: 8-10, SEQ ID NO: 14-16, SEQ ID NO: 18, SEQ ID NO: 20-31, and any combination of these peptides.
- the peptides distinctive of G3m and/or IGHG3 alleles useful for determining a haplotype of the "Asian" type are the peptides of sequence SEQ ID NO: 1-10, SEQ ID NO: 12-16, SEQ ID NO: 19-21, SEQ ID NO: 24-25, SEQ ID NO: 28-29, SEQ ID NO: 32, and any combination of these peptides.
- the peptides distinctive of G3m and/or IGHG3 alleles useful for determining a haplotype of the "European" type are the peptides of sequence SEQ ID NO: 2-3, SEQ ID NO: 5-6, SEQ ID NO: 8, SEQ ID NO: 10, SEQ ID NO: 13-14, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 21 , SEQ ID NO: 25, SEQ ID NO: 29, SEQ ID NO: 32, and any combination of these peptides.
- the kit may further comprise reagents or solutions for preparing calibration samples.
- the various components of the kit may be supplied in solid form (for example in lyophilized form) or in liquid form.
- a kit can optionally include containers containing each of the reagents or solutions, and/or containers (test tubes, bottles, etc.) for carrying out preparation of the calibration samples.
- the kit may also further comprise reagents for preparing the blood sample to be analyzed (e.g., reagents necessary for isolating the IgG3s, and/or reagents necessary for enzymatic digestion of the IgG3s, etc.). These reagents may be comprised in containers included in the kit.
- kit may further comprise a notice in the form prescribed by a governmental agency regulating the sale and use of products for medical or pharmaceutical use. Unless they are defined otherwise, all technical and scientific terms used herein have the same meaning as that commonly understood by an ordinary specialist in the field to which this invention belongs. In addition, all the publications, patent applications, all the patents and all other references mentioned here are incorporated by reference.
- proteotypic peptides was established based on a comparison of the peptide sequences of four IGHG proteins. The sequences were cleaved virtually by the endoproteinase AspN and trypsin with or without missing enzymatic cleavage. All the peptides obtained by theoretical enzymatic digestion were compared in order to determine those that are specific of IGHG3 and discriminatory with respect to alleles. A list was defined comprising 32 proteolytic peptides suitable for analysis using a MALDI-TOF/TOF technique or an Orbitrap technique or yet an SRM technique. 2. Plasma samples used in the purification and digestion protocols
- the samples analysed in this study came from two separate geographical regions: Europe and Africa.
- the European blood samples were obtained from adult volunteers in good health of French origin. Five (5) millilitres of blood were collected in Vacutainer ® EDTA tubes. After centrifugation, 1 mL of fresh plasma was purified and aliquot fractions were prepared from the remaining plasma and were frozen at -20°C for later use.
- the African plasma samples were obtained during two studies carried out in Benin by the inventors' team.
- the first study conducted in 2006-2007, related to 155 children mainly belonging to the Fon ethnic group (Migot-Nabias et al., J. Infect. Dis., 2008, 198: 1892-1895).
- Blood samples were collected in 5-mL Vacutainer ® EDTA tubes, and after centrifugation, plasma samples were prepared and frozen at -20°C.
- a cohort of 627 neonates in a semi-rural region in the south of Benin and their mothers was constituted and monitored from 2007 to 2010 (Le Port et al., in preparation).
- a blood sample from the mother as well as the cord blood were collected in Vacutainer ® EDTA tubes. Then, a blood sample from each child was collected every three months up to the age of 18 months.
- the plasma samples were stored at -80°C. Samples obtained from the mother at the time of birth and from her child (cord blood and plasma samples obtained at 3, 6 and 9 months after birth) were used in the present study.
- the Gm allotypes of the plasma specimens were analyzed by the standard qualitative method of haemagglutination inhibition (Dugoujon et al., Vox Sanguinis, 1989, 57: 133-136; Field and Dugoujon, Gen. Epidem., 1989, 6: 31-33). Briefly, erythrocytes of human blood of group O Rh+ were coated with anti-Rh antibodies of known Gm allotypes, plasma samples, and monospecific anti-allotype antibodies. After sedimentation, the plasma specimens containing IgGs of a particular allotype inhibit haemagglutination by the anti-allotype antibody whereas the plasma specimens that tested negative for the relevant IgG do not cause inhibition. 4. Purification of the total IgG3s
- the plasma obtained from freshly collected blood samples was purified directly and the samples of frozen plasma were used after centrifugation to remove the fibrin aggregates.
- a volume of 250 ⁇ , of plasma is sufficient for detecting and quantifying the peptides of the purified total IgG3s.
- a column (HiTrap Protein A HP, GE Healthcare) of Protein A was used for the first purification step, which was carried out according to the supplier's instructions. This column is used for retaining the IgGl, IgG2 and IgG4 interfering immunoglobulins, allowing the IgG3 immunoglobulins to pass through into the filtrate. The retention of IgGl, IgG2 and IgG4 in the Protein A column requires low ionic strength, pH 7.
- the reactions of reduction, alkylation and enzymatic digestion were carried out either in solution, or on bands of 12% acrylamide gel corresponding to the heavy chains of the IgGs after electrophoretic migration of the purified samples in reducing conditions.
- Several enzymes were tested, alone or combined, including: papain, GluC, PNGase, AspN and trypsin.
- the objective was to select the enzyme or enzymes enabling the largest number of G3m and IGHG3 allelic discriminatory peptide sequences to be contained within a range of masses accessible to high-resolution mass spectrometers.
- a combination of AspN and trypsin at a final concentration of 10 ng/ ⁇ gave the best result.
- the samples of gels were decolorized with 50% acetonitrile, submitted to reduction in the presence of 20 mM of DTT for 30 minutes at 56°C, and to alkylation in the presence of 25 mM of chloroacetamide for 30 minutes at room temperature to protect the thiol groups of the proteins.
- 1 ⁇ _ of AspN (10 ng/mL, Roche) was added to the gel.
- the samples were incubated overnight at 30°C or for 3 hours at 37°C. Additional digestion was carried out with 2 ⁇ _, of freshly activated trypsin (10 ng/mL, Modified Sequencing Grade from Promega).
- the supernatants were collected and replaced with 10 of formic acid (4%) for 5 minutes at room temperature. After a step of sonication for 30 seconds, the supernatant was collected and replaced with 50%> acetonitrile to dehydrate the gel and extract the peptides from the gel. At each step, the supernatants were collected, and fully dehydrated under vacuum. The samples were resuspended in a mixture of 10% acetonitrile and 0.1% trifluoroacetic acid (TFA). Using the samples of IgG in solution. DTT was added to a final concentration of
- Nanochromatography The peptides of the samples obtained after enzymatic digestion were concentrated and separated by HPLC (Ultimate3000, Dionex). Briefly, 10 ⁇ of eluate were injected in a CI 8 precolumn (Acclaim pepmaplOO CI 8, particles of 5 ⁇ , pore size 100 A, inside diameter 300 ⁇ , and length 5 mm).
- the peptides were then eluted (300 nL/min) to the analytical column (C18pepmapl00, 3 ⁇ particles, pore size 100 A, inside diameter 75 ⁇ and length 15 cm) with a gradient from 7% of solvent B (80% acetonitrile, 20% solvent A) at the moment of introduction of the peptides in the analytical column to 20% of solvent B in 7 minutes and from 20% of solvent B to 60% of solvent B in 58 minutes.
- the fractions were mixed in 1 :9 ratio with 3 mg/rnL of HCCA (Laser Bio labs) in 70% of acetonitrile (Carlo Erba), 0.1% of TFA (Pierce) and Glu-fibrinopeptide at 3 fmol/spot. In all, 192 fractions were collected and analysed using a 4800 MALDI TOF/TOF analyser (AM).
- MALDI spectrometry Acquisition and processing of the mass spectra were carried out with the 4000 series explorer software (ABSciex, version 3.5.28193 build 1011) in positive reflectron mode at constant laser fluence with filtering of the low-mass ions, and delayed extraction. External calibration of the plate was performed using 4 calibration points distributed over the plate. In addition, internal calibration using Glu- fibrinopeptide gave a measurement accuracy below 10 ppm. For each fraction, 10 series of 50 spectra were recorded in the range from 700 to 4000 kDa at a laser frequency of 200 Hz. For each sample, the 500 raw spectra added were processed to obtain monoisotopic values from isotopic masses with signal/noise ratios of min. 20.
- MALDI-MS/MS spectrometry In each mass spectrum, the 8 most abundant peaks were selected for fragmentation beginning with the least abundant. The close precursors in a resolution of 200 were excluded. For each precursor, 1000 MS/MS spectra were added in increments of 50. The spectra were processed as follows: subtraction of the base line, Savitzky-Golay smoothing with 3 points on the peak and a polynomial order of 4. The lists of peaks reflect the monoisotopic values of the isotope clusters with a minimum signal/noise ratio of 22. The lists of peaks generated in MS/MS were then submitted to a Mascot internal search engine (Matrix science), version 2.2 to identify the peptides (see below).
- Mascot internal search engine Mascot internal search engine
- LTQ-ORBITRAP MS and MS/MS spectrometry were performed with a liquid chromatography system with fast separation (Ultimate 3000 RSLC, Dionex) coupled to a mass spectrometer (LTQ-Orbitrap Velos, Thermo Fisher Scientific). Briefly, the peptides obtained by enzymatic digestion were loaded on a reverse-phase precolumn (CI 8, 3 ⁇ particles, pore size 100 A, inside diameter 75 ⁇ , and length 2 cm) with a loading solvent containing 98% water, 2% acetonitrile and 0.1%) trifluoroacetic acid at 5 ⁇ / ⁇ .
- the peptides were separated on a reverse- phase analytical column (CI 8, 2 ⁇ particles, pore size 100 A, inside diameter 75 ⁇ , and length 15 cm) with a gradient of 45 minutes ranging from 100% of solvent A (5% acetonitrile, 0.1% AF and 95% water) to 40% of solvent B (80% acetonitrile, 0.085% formic acid and 20% water).
- the mass spectrometer (LTQ-Orbitrap) used acquired the data throughout the elution process and operated as follows: the MS scans were acquired with the Orbitrap, followed by up to 10 spectra of LTQ MS/MS CID on the most abundant precursors detected in the MS scans. Exclusion of latency was fixed at 24 seconds for the previously fragmented precursors.
- the settings used for the mass spectrometer were as follows: MS (AGC: lxlO 6 , resolution: 3xl0 4 , m/z of 400-2000, maximum ion injection time: 1000 ms); MS/MS (AGC: lxlO 4 , maximum ion injection time: 200 ms, minimum signal threshold: 2000, width of isolation: 2 Da). Fragmentation was permitted for precursors with a charge state of 2 or 3. Processing the spectra.
- the software used for extracting the lists of peaks and generating the mgf (mascot generic file) files was Proteome discoverer 1.2 with a threshold value of signal to noise of 3.
- the MS/MS spectra obtained by the two mass spectrometers were submitted to a Mascot internal search engine (Matrix science), version 2.2 to identify the peptides.
- the database searched was a "Parasitoswissprot” database developed internally (resulting from concatenation of the IgHG Immunoglobulin- variants database from IMGT with the Plasmodium fasta database "plasmoDB” and the Swissprot fasta database, i.e. in a total of 529942 sequences, 189364547 residues).
- the mass tolerance for the precursors was fixed at 20 ppm for MALDI and 3 ppm in Orbitrap.
- the Progenesis software (Version 3.0; Nonlinear Dynamics Ltd.) was used for quantifying the variation of the discriminating peptides based on the retention time, the m/z ratio and the peak intensity (peak area) of the samples.
- the Progenesis software processes the raw data files obtained from the Orbitrap in two steps: alignment followed by normalizing. The data file that led to the largest number of characteristics (1 : 1 ratio) was used as reference, for aligning the retention time with the other measurements. The experimental variations were corrected by calculating the robust distribution of all the ratios (log(ratio)).
- the chromatographic peaks (the events) were converted to a list of intensities and retention times using the raw data files. The data were filtered, conserving the events according to the following criteria: mass/charge ratio in the range 300-1700, retention time 8-25 minutes, and charge state from 2 to 4.
- Mascot generic files (mgf) were exported from Progenesis and imported into Mascot software; and the Parasitoswissprot database was interrogated (taxonomy: mammals, enzyme: AspN+trypsin, fixed modification: carbamidomethylation, variable modification: oxidation, number of missing cleavages allowed: up to 2, peptide tolerance: +/- 5 ppm, MS/MS tolerance: +/-
- SRM acquisitions were performed in scheduled mode.
- the SRM transitions (precursor/product pairs) were recorded at the retention time +/- 4 minutes as measured during the optimization step.
- the dwell time associated to the SRM method was less than 2 seconds.
- the first and third quadrupole were set to 0.7 Da peak width.
- dwell time 100 ms was used.
- the sensitivity threshold tested with AQUA peptides was 10 fmol of injected peptide.
- SRM data processing and absolute quantitation using AQUA peptides were performed by Pinpoint version 1.2 (Thermo Fisher, Germany).
- the French individual has a phenotype Gm5, 10,11,13,14,26,27;3 comprising the alleles G3m5, 10, 11,13,14,26,27 and Glm3, which are commonly associated with the Gm haplotypes of individuals of European origin.
- the plasma samples from a mother and her child were selected from a multidisciplinary study on malaria carried out in Benin in 2007-2010.
- Serological determination identified a phenotype Gm5,6,10,l 1,13,14,24,26,27,28;1,17 for the mother (individual A170M) and a phenotype Gm5, 10,11,13, 14,26,27;1, 17 for the child (serological determination carried out on the plasma from A170M15 collected at age 15 months).
- the fraction AF On the unreduced gel, the fraction AF (3 wells) consisted of IgG3 with a band at about 160 kDa and of several other plasma proteins, which are represented by the other bands.
- the fraction AE the IgGl, IgG2 and IgG4 and other plasma proteins were eluted.
- the fraction GE (2 wells) contained contamination with plasma proteins. Washing of these fractions (3 wells) removed most of the contaminating proteins.
- the first eluate GEl from the column of Protein G was contaminated with plasma proteins but the IgGs were present predominantly.
- the fractions from washing (3 wells) had a band of 60 kDa. It is possible that certain immunoglobulins were lost during the washing steps.
- Table 3 ELISA assay of the IgG subclasses contained in the purification fractions obtained from passage of a plasma sample on columns of Protein A and then Protein G.
- Table 4 List of the 32 peptides distinctive of IGHG3 alleles observable after theoretical cleavage of the heavy chain of the IgG3s by an AspN / trypsin combination.
- Table 5 Correspondence between the IGHG3 alleles and the G3m alleles.
- Figure 2 presents the 32 peptides, also showing the enzymatic cleavage sites as well as the amino acids before and after the enzymatic cleavages.
- Figure 2 also lists the corresponding masses of these peptides, determined for measurement with MALDI-MS and with ESI-MS.
- Table 6 summarizes the characteristics of the discriminatory peptides. Twenty-three (23) of the peptides are discriminatory of one single G3m allele.
- Each of the peptides of SEQ ID NO: 21 and of SEQ ID NO: 25 corresponds to two different G3m alleles: G3m5* and G3m21 *.
- the detection of another peptide should be required for an unambiguous G3m assignment, e.g. detection of the peptide of SEQ ID NO: 16 for G3m5* and detection of the peptide of SEQ ID NO: 19 for G3m21 *, in the absence of serological data.
- Table 6 Characteristics of the 32 proteotypic peptides for Homo sapiens G3 IGHG3 alleles.
- the IGHG3* 11 and IGHG3* 12 alleles differ by the number of hinge exons, 4 and 3, respectively (IMGT Repertoire, Gene table www.imgt.org). b ' c
- Amino acids characteristic of the G3m allotypes and IGHG3 alleles are from Lefranc et al, Methods Mol. Biol, 2012, 882: 635-680. They are illustrated in the 'IMGT G3m allele butterfly' representation. Amino acid sequences are available in the IMGT Repertoire (www.imgt.org), IMGT/DomainDisplay and IMGT/GENE-DB. b Positions in the CH domains are according to the IMGT unique numbering for C domain. a
- the experiments were carried out on a series of controlled mixtures of plasma samples from two individuals in Benin who were found, by a serological method, to be homozygous for the alleles G3m5, 10,11,13,14,26,27 and G3m5, 6,11,24,26, respectively.
- the results of determination by mass spectrometry according to the invention show the presence of the peptide sequence WQQGNIFSCSVMHEALHNR for the first individual and of the peptide sequence WQEGNVFSCSVMHEALHNR for the second individual.
- Mixing with volume/volume ratios as indicated in Figure 4 was carried out before reduction, alkylation and enzymatic digestion.
- the IGHG3 alleles that they make it possible to distinguish correspond to the G3m alleles as follows (Lefranc et al., "Human Gm, Km and Am allotypes and their molecular characterization: a remarkable demonstration of polymorphism", In: Methods in Molecular Biology, Eds. B. Trait and F. Christiansen, in press):
- DIAVEWESSGQPENNYNTTPPML (SEQ ID NO: 16) is distinctive of the alleles IGHG3*01, *04, *05, *09 to * 13.
- WQQGNIFSCSVMHEALHNR (SEQ ID NO: 25) is distinctive of the alleles IGHG3*01, *02, *06 to * 12, * 14 to * 16;
- WQEGNVFSC C SVMHEALHNR (SEQ ID NO: 26) is distinctive of the allele IGHG3 *03, where IGHG3*01, *05, *06, *07, *09, * 10, * 11, * 12 corresponds to the allele G3m5,l 0,11,13,14,26,27; IGHG3* 13 corresponds to the allele G3m5, 6, 10, 11,14,26,27; IGHG3*3 corresponds to the allele G3m5,6, 11,24,26 and IGHG3* 14, * 15, * 16 corresponds to the allele G3m21,26,27,28.
- G3m polymorphism is not as extensive in certain groups of populations distributed throughout the world (Dugoujon et al, Am. J. Phys. Anthrop., 2004, 125: 175-192). In these cases, it will be necessary to resort to Glm polymorphism (4 IGHG1 alleles) to be sure of having the capacity to distinguish the IGHG alleles of the mother and of the child.
- SRM Selected Reaction Monitoring
- the WQEGNVFSCSVMHEALHNR peptide was expected in the mother's sample (CI) as well as in the samples corresponding the first months of life of her child (CO, M3, M6), but it was not visualized.
- the expected peptides DIAVEWESSGQPENNYNTTPPVL and DIAVEWESSGQPENNYNTTPPML were not observed in the Orbitrap. The detection threshold of these peptides seems to be too low in the sample.
- the optimized SRM strategy was used to monitor the WQEGNVFSCSVMHEALHNR and WQQGNIFSCSVMHEALHNR peptides with their corresponding AQUA peptides.
- the WQQGNIFSCSVMHEALHNR peptide was found and quantified in agreement with the Orbitrap data ( Figure 5B) but the detection of peptide WQEGNVFSCSVMHEALHNR was not possible in this particular case of mother-child pair samples.
- BEM1 could be homozygous for the G3m5* allele inversely to the results provided by the hemagglutination inhibition method or ii) the WQEGNVFSCSVMHEALHNR signal was undetected because it was lower than the signal/noise ratio.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Optics & Photonics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/238,107 US9493811B2 (en) | 2011-08-11 | 2012-08-10 | Method of neonatal serological diagnosis |
EP12755809.6A EP2742360B1 (en) | 2011-08-11 | 2012-08-10 | Method of neonatal serological diagnosis |
BR112014003159A BR112014003159B8 (en) | 2011-08-11 | 2012-08-10 | NEONATAL SEROLOGICAL DIAGNOSIS METHOD |
EP19160574.0A EP3517965A3 (en) | 2011-08-11 | 2012-08-10 | Method of neonatal serological diagnosis |
BR122020018640A BR122020018640B8 (en) | 2011-08-11 | 2012-08-10 | NEONATAL SEROLOGICAL DIAGNOSIS METHOD |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1157296A FR2979019A1 (en) | 2011-08-11 | 2011-08-11 | METHOD OF NEONATAL SEROLOGICAL DIAGNOSIS |
FR1157296 | 2011-08-11 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2013021057A2 true WO2013021057A2 (en) | 2013-02-14 |
WO2013021057A3 WO2013021057A3 (en) | 2013-06-13 |
WO2013021057A4 WO2013021057A4 (en) | 2013-08-01 |
Family
ID=46799202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2012/065737 WO2013021057A2 (en) | 2011-08-11 | 2012-08-10 | Method of neonatal serological diagnosis |
Country Status (5)
Country | Link |
---|---|
US (1) | US9493811B2 (en) |
EP (2) | EP3517965A3 (en) |
BR (2) | BR112014003159B8 (en) |
FR (1) | FR2979019A1 (en) |
WO (1) | WO2013021057A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109900815B (en) * | 2017-12-08 | 2021-06-29 | 中国科学院大连化学物理研究所 | Absolute quantitative analysis of IgG glycopeptides in serum |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7183387B1 (en) * | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
-
2011
- 2011-08-11 FR FR1157296A patent/FR2979019A1/en active Pending
-
2012
- 2012-08-10 BR BR112014003159A patent/BR112014003159B8/en active IP Right Grant
- 2012-08-10 US US14/238,107 patent/US9493811B2/en active Active
- 2012-08-10 WO PCT/EP2012/065737 patent/WO2013021057A2/en active Application Filing
- 2012-08-10 EP EP19160574.0A patent/EP3517965A3/en not_active Withdrawn
- 2012-08-10 BR BR122020018640A patent/BR122020018640B8/en active IP Right Grant
- 2012-08-10 EP EP12755809.6A patent/EP2742360B1/en active Active
Non-Patent Citations (19)
Title |
---|
C. DECHAVANNE ET AL.: "Mass spectrometry detection of G3m and IGHG3 alleles and follow-up of differential mother and neonate IgG3", PLOS ONE, 30 July 2012 (2012-07-30) |
CHIPPAUX ET AL., TROPICAL MED. INTERNATIONAL HEALTH, vol. 15, 2010, pages 87 - 93 |
DUGOUJON ET AL., AM. J. PHYS. ANTHROP., vol. 125, 2004, pages 175 - 192 |
DUGOUJON ET AL., VOX SANGUINIS, vol. 57, 1989, pages 133 - 136 |
FATOOHI ET AL., CLIN. DIAG. LAB. IMMUNOL., vol. 9, 2001, pages 704 - 707 |
FIELD; DUGOUJON, GEN. EPIDEM., vol. 6, 1989, pages 31 - 33 |
FIELD; DUGOUJON, GEN. EPIDEMIOL., vol. 6, 1989, pages 31 - 33 |
FIEVET ET AL., AM. J. TROP. MED. HYG., vol. 53, 1995, pages 612 - 617 |
FLECHAS ET AL., BMC INFECTIOUS DISEASES, vol. 9, 2009, pages 186 |
LEFRANC ET AL., ACTA ANTHROPOGENETICA, vol. 1, 1976, pages 34 - 45 |
LEFRANC ET AL.: "Methods in Molecular Biology", article "Human Gm, Km and Am allotypes and their molecular characterization: a remarkable demonstration of polymorphism" |
LEFRANC; LEFRANC: "The Human IgG Subclasses: Molecular analysis of structure, function and regulation", 1990, PERGAMON PRESS, pages: 43 - 78 |
MIGOT-NABIAS ET AL., J. INFECT. DIS., vol. 198, 2008, pages 1892 - 1895 |
NEBIE ET AL., INFECTION AND IMMUNITY, vol. 76, 2008, pages 759 - 766 |
PINON ET AL., J. CLIN. MICROBIOL., vol. 39, 2001, pages 2267 - 2271 |
SCHIJMAN ET AL., J. ANTIMICROB. CHEMOTHER., vol. 52, 2003, pages 441 - 449 |
SHEEHAN ET AL., METH. MOL. BIOL., vol. 244, 2004, pages 253 - 258 |
SIMISTER ET AL., J. REPROD. IMMUN., vol. 37, 1997, pages 1 - 23 |
WILLIAMS ET AL., ARCH. DIS. CHILDHOOD, vol. 44, 1969, pages 511 - 514 |
Also Published As
Publication number | Publication date |
---|---|
US20140178916A1 (en) | 2014-06-26 |
EP3517965A3 (en) | 2019-09-11 |
BR122020018640B8 (en) | 2022-12-13 |
BR112014003159B8 (en) | 2022-11-22 |
BR112014003159A2 (en) | 2018-09-11 |
BR112014003159B1 (en) | 2022-03-08 |
EP3517965A2 (en) | 2019-07-31 |
WO2013021057A3 (en) | 2013-06-13 |
BR122020018640B1 (en) | 2022-02-22 |
WO2013021057A4 (en) | 2013-08-01 |
US9493811B2 (en) | 2016-11-15 |
FR2979019A1 (en) | 2013-02-15 |
EP2742360A2 (en) | 2014-06-18 |
EP2742360B1 (en) | 2019-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Plomp et al. | Comparative glycomics of immunoglobulin A and G from saliva and plasma reveals biomarker potential | |
EP3387898B1 (en) | Identification and monitoring of monoclonal immunoglobulins by molecular mass | |
JP2015513370A (en) | Citrullinated brain and neuroproteins as biomarkers of brain injury or neurodegeneration | |
Schramm et al. | Molecular characterisation of kappa-5, a major antigenic glycoprotein from Schistosoma mansoni eggs | |
EP3859332A1 (en) | Glycated hemoglobin (%) assay method | |
WO2010032458A1 (en) | Novel biomarker for non-alcoholic fatty liver disease, and method for detecting non-alcoholic fatty liver disease by using the biomarker | |
EP3535587B1 (en) | Mass spectrometry-based methods for the detection of circulating histones h3 and h2b in plasma from sepsis or septic shock (ss) patients | |
EP2742360B1 (en) | Method of neonatal serological diagnosis | |
EP2860250B1 (en) | Method for detecting cancer, and antibody capable of recognizing pancreas-specific ribonuclease 1 | |
KR20150140657A (en) | Methods and compositions for diagnosing preeclampsia | |
WO2023069725A1 (en) | Methods of diagnosing or treating lyme disease | |
Lanyon et al. | Resolving omicron sub-variants of SARS CoV-2 coronavirus with MALDI mass spectrometry | |
US20210285965A1 (en) | Proteomic screening for diseases | |
Mandal et al. | Electrospray mass spectrometric characterization of hemoglobin Q (Hb Q-India) and a double mutant hemoglobin S/D in clinical samples | |
WO2011138955A1 (en) | METHOD OF ANALYSIS FOR MUCIN 1 HAVING SUGAR CHAIN OF Siaα2-8Siaα2-3Galβ-R | |
Turčić et al. | Higher MRI lesion load in multiple sclerosis is related to the N-glycosylation changes of cerebrospinal fluid immunoglobulin G | |
Sadeghi et al. | Evaluation of the Plasma Level of Fibrinogen in the First Trimester in Mothers with Toxoplasmosis | |
AU2019101124A4 (en) | Method of diagnosing systemic lupus erythematosus | |
US9429583B2 (en) | System and method for quantifying fragile X mental retardiation 1 protein in tissue and blood samples | |
EP2877852B1 (en) | A protein microarray for characterizing the specificity of the monoclonal immunoglobulins of mgus or myeloma patients | |
EP3919503A1 (en) | Method for identifying helicobacter pylori strain and kit for identification | |
Plomp et al. | Comparative Glycomics of ImmunoglobulinAand GfromSalivaand Plasma Reveals Biomarker Potential | |
KR102141546B1 (en) | Method of predicting hearing loss prognosis and kit using the same | |
JP2020016453A (en) | Peptide marker for disease associated with septicemia | |
JP2020064051A (en) | Peptide marker for diagnosis of neurodegenerative diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12755809 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14238107 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012755809 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014003159 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014003159 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140210 |